Professor of Paediatric Immunology and Infectious Diseases
University of Southampton and University Hospital Southampton NHS Foundation Trust
Southampton, England, United Kingdom
Saul Faust FRCPCH PhD FHEA OBE (https://scholar.google.co.uk/citations?user=ZYhyFooAAAAJ&hl=en), is Professor and Hon consultant of Paediatric Immunology & Infectious Diseases at the University of Southampton and University Hospital Southampton NHS Foundation Trust. Saul is Director of the National Institute for Health Research (NIHR) Southampton Clinical Research Facility, Clinical Director of the NIHR Wessex Local Clinical Research Network, joint national clinical lead for the new NIHR Vaccine Innovation Network and a NIHR Senior Investigator.
Saul is a clinical researcher with projects bridging the clinical-laboratory interface, developing local and national collaborative clinical trials for paediatric and adult vaccines and antimicrobials. Saul is Deputy lead for the NIHR Southampton BRC Microbiology, Immunology and Infection Theme. Saul’s research includes early phase vaccine trials and collaborations to investigate new diagnostic tools and treatments for antimicrobial resistant infections, including clinical biofilm infections.
Saul is a member of the National Immunisation Schedule Evaluation Consortium (NISEC) and is UK Chief Investigator for the UK national COV-BOOST trial. Saul Chairs the RECOVERY trial paediatric working group, the UK Clinical Research Facilities Directors Committee, the University Hospital Association R&D Directors Group, and is a member of the National Institute for Health Research Health Technology Programme Commissioning Board.
Outside of research, Saul is the NHS England national speciality lead for paediatric allergy, immunology and infectious diseases, and he chaired the UK NICE Guideline Committees for sepsis in children and adults (2016) and for Lyme Disease (2018).
Disclosure(s): AstraZeneca: Grant/Research Support; BioNTech: Grant/Research Support; GSK: Grant/Research Support; Iliad Biotechnologies: Grant/Research Support; J&J: Advisor, no personal payments (all honoraria paid to employing hospital), Grant/Research Support; Moderna: Grant/Research Support; Novavax: Advisor, no personal payments (all honoraria paid to employing hospital); Pfizer: Advisor, no personal payments (all honoraria paid to employing hospital); Sanofi: Advisor, no personal payments (all honoraria paid to employing hospital), Grant/Research Support; Valneva: Grant/Research Support
Thursday, October 17, 2024
11:30 AM – 11:45 AM US PT